NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ACCENTMIC · data 2026-11-01
Accent Microcell Limited
In plain words
Price: 12.7% below its 52-week high of ₹731.7.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹385 cr |
| Net profit (last 12 months) | ₹57 cr |
| Sales growth, 3 years (yearly) | 20.9% |
| Profit growth, 3 years (yearly) | 53.1% |
At a glance
P/E 26.9, P/B 5.0, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.7%, ROCE 22.7%, operating margin 18.0%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 53.1% and sales growth 20.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (18.7%).
- Profit grew 53.1% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Accent Microcell Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Accent Microcell Limited's P/E ratio?
About 26.9, based on the last 12 months' earnings and a price of ₹639 (data 2026-11-01).
What is the 52-week high and low of Accent Microcell Limited?
The 52-week high is ₹731.7 and the 52-week low is ₹273.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Accent Microcell Limited | ₹639 | ₹1,533 cr | 26.9 | 5 | 18.7% | 22.7% | 0 | +140.2% |
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,810 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
| Venus Remedies Limited | ₹1,238.6 | ₹1,646 cr | 13.6 | 2.4 | 16.8% | 14.5% | 0.02 | +182.9% |
| NGL Fine-Chem Ltd. | ₹2,526 | ₹1,576 cr | 27.3 | — | 15.7% | 17.1% | 0.37 | +66.0% |
| Bharat Parenterals Ltd. | ₹2,029.9 | ₹1,397 cr | 1,124.7 | 4.2 | -2.5% | -4.2% | 0.45 | +45.0% |
| Anlon Healthcare Limited | ₹25.89 | ₹1,378 cr | 38.6 | 5.4 | 18.4% | 24.3% | 0.19 | +108.0% |
Compare ACCENTMIC with SYNCOMF in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ACCENTMIC in NSE Scanner →